Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Castro

Showing results (141-150 of 194) with videos related to

Pageof 20
Sort By:
The Lancet. Oncology|October 13, 2012
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage studyDavid Olmos, Daniel Brewer, Jeremy Clark, et al.
Revista Espanola De Geriatria Y Gerontologia|June 25, 2026
Is dexmedetomidine effective for delirium prevention in older adults? A scoping reviewLucía Lozano-Vicario, Maria Cristina Ferrara, Elisabet Sánchez-García, et al.
The Oncologist|September 20, 2022
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety AnalysesNiven Mehra, Karim Fizazi, Johann S de Bono, et al.
European Journal of Cancer (Oxford, England : 1990)|June 2, 2021
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker studyVincenza Conteduca, Daniel Wetterskog, Elena Castro, et al.
Plos One|April 15, 2020
Circulating miRNome detection analysis reveals 537 miRNAS in plasma, 625 in extracellular vesicles and a discriminant plasma signature of 19 miRNAs in children with retinoblastoma from which 14 are also detected in corresponding primary tumorsBlanca Elena Castro-Magdonel, Manuela Orjuela, Diana E Alvarez-Suarez, et al.
Gaceta Medica De Mexico|October 30, 2016
[Level of expression of gene CTSL and its correlation with natural killer T-Cells in mexican pediatric patients with recent-onset type 1 diabetes]Rita Angélica Gómez-Díaz, Roberto Medina-Santillán, Blanca Elena Castro-Magdonel, et al.
The Oncologist|May 7, 2016
The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate CancerElena Castro, Christos Mikropoulos, Elizabeth K Bancroft, et al.
European Urology Open Science|February 22, 2024
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 StudyChiara Casadei, Emanuela Scarpi, Vincenza Conteduca, et al.
The Lancet. Oncology|August 13, 2021
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trialJohann S de Bono, Niven Mehra, Giorgio V Scagliotti, et al.
European Urology Oncology|May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE TrialKim N Chi, Elena Castro, Gert Attard, et al.
Pageof 20

Showing results (141-150 of 194) with videos related to

Sort By:
Pageof 20
The Lancet. Oncology|October 13, 2012
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage studyDavid Olmos, Daniel Brewer, Jeremy Clark, et al.
Revista Espanola De Geriatria Y Gerontologia|June 25, 2026
Is dexmedetomidine effective for delirium prevention in older adults? A scoping reviewLucía Lozano-Vicario, Maria Cristina Ferrara, Elisabet Sánchez-García, et al.
The Oncologist|September 20, 2022
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety AnalysesNiven Mehra, Karim Fizazi, Johann S de Bono, et al.
European Journal of Cancer (Oxford, England : 1990)|June 2, 2021
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker studyVincenza Conteduca, Daniel Wetterskog, Elena Castro, et al.
Plos One|April 15, 2020
Circulating miRNome detection analysis reveals 537 miRNAS in plasma, 625 in extracellular vesicles and a discriminant plasma signature of 19 miRNAs in children with retinoblastoma from which 14 are also detected in corresponding primary tumorsBlanca Elena Castro-Magdonel, Manuela Orjuela, Diana E Alvarez-Suarez, et al.
Gaceta Medica De Mexico|October 30, 2016
[Level of expression of gene CTSL and its correlation with natural killer T-Cells in mexican pediatric patients with recent-onset type 1 diabetes]Rita Angélica Gómez-Díaz, Roberto Medina-Santillán, Blanca Elena Castro-Magdonel, et al.
The Oncologist|May 7, 2016
The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate CancerElena Castro, Christos Mikropoulos, Elizabeth K Bancroft, et al.
European Urology Open Science|February 22, 2024
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 StudyChiara Casadei, Emanuela Scarpi, Vincenza Conteduca, et al.
The Lancet. Oncology|August 13, 2021
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trialJohann S de Bono, Niven Mehra, Giorgio V Scagliotti, et al.
European Urology Oncology|May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE TrialKim N Chi, Elena Castro, Gert Attard, et al.
Pageof 20